x
Filter:
Filters applied
- Reviews
- Andreone, PRemove Andreone, P filter
Keyword
- ABVD1
- Alcohol1
- Antivirals1
- ART1
- Child-Turcotte-Pugh1
- CHOP1
- Chronic hepatitis1
- Cirrhosis1
- Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone1
- D1
- Doxorubicine, Bleomycin, Vinblastine, Dacarbazine (standard therapy for Hodgkin lymphoma)1
- End-stage liver disease1
- Graft versus Host Disease1
- GvHD1
- HAI1
- HBeAg1
- HBIG1
- HBsAg1
- HBV1
- HCV1
- HDV1
- Hepatitis B1
- Hepatitis C1
- HIV1
- HSCT1
Reviews
3 Results
- Review Article
Allocation priority in non-urgent liver transplantation: An overview of proposed scoring systems
Digestive and Liver DiseaseVol. 41Issue 10p700–706Published online: June 8, 2009- S. Gitto
- S. Lorenzini
- M. Biselli
- F. Conti
- P. Andreone
- M. Bernardi
Cited in Scopus: 8Given the lack of donors, a correct organ allocation system for candidates to liver transplantation is essential to increase graft and patient survival. The most used organ allocation tools are Child–Turcotte–Pugh and model for end-stage liver disease. It is generally accepted that model for end-stage liver disease score is superior to the Child–Turcotte–Pugh classification in predicting the short-term survival of cirrhotic patients awaiting liver transplantation. Since 2002, model for end-stage liver disease is widely used for liver allocation. - Progress Report
Alcohol and viral hepatitis: A mini-review
Digestive and Liver DiseaseVol. 41Issue 1p67–70Published online: July 4, 2008- S. Gitto
- L. Micco
- F. Conti
- P. Andreone
- M. Bernardi
Cited in Scopus: 47Due to their high prevalence in the general population, alcohol use and abuse can be associated with hepatitis B and C virus infections and it has been demonstrated that alcohol plays a role as a co-morbid factor in the development of liver disease. There is evidence that alcohol abuse accelerates the progression of liver fibrosis and affects the survival of patients with chronic hepatitis C. The mechanism by which alcohol worsens hepatitis C virus-related liver disease has not been fully clarified, but enhanced viral replication, increased oxidative stress, cytotoxicity and impairment of immune response could play a relevant role. - Review Article
Prophylaxis and treatment of hepatitis B in immunocompromised patients
Digestive and Liver DiseaseVol. 39Issue 5p397–408Published in issue: May, 2007- A. Marzano
- E. Angelucci
- P. Andreone
- M. Brunetto
- R. Bruno
- P. Burra
- and others
Cited in Scopus: 200The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and referred mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: (a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), (b) the treatment with antivirals (therapy) of active carriers, (c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, (d) the biochemical and hepatitis B surface antigen (HBsAg) monitoring (or universal prophylaxis, in case of high risk immunosuppression) in subjects with markers of previous contact with HBV (HBsAg negative and anti-HBc positive), in order to prevent reverse seroconversion.
